abemaciclib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Cyclin-dependent kinase 4.
- Target
- Cyclin-dependent kinase 4
- Mechanism
- Cyclin-dependent kinase 6 inhibitor
pharma · Myelofibrosis · Acute Myeloid Leukemia
Karyopharm Therapeutics
Karyopharm Therapeutics Inc
Karyopharm Therapeutics drug portfolio — 53 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
85 Wells Avenue, Newton, MA 02459, US HQ
313 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 85 Wells Avenue, Newton, MA 02459, US
- Employees
- 313
- Programs
- 82
- Drugs
- 53
- Patents
- 38
Karyopharm Therapeutics pipeline
Portfolio lens on 53 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Karyopharm Therapeutics drug portfolio — 53 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Karyopharm Therapeutics in public FDA and regional records.
-
aprepitant
Alimentary tract and metabolism (A04)US regulatory status: approved. Molecular target: Substance-P receptor.
- Target
- Substance-P receptor
- Mechanism
- Neurokinin 1 receptor antagonist
-
bortezomib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: 26S proteasome.
- Target
- 26S proteasome
- Mechanism
- 26S proteosome inhibitor
-
capecitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to Karyopharm Therapeutics in public FDA and regional records.
-
Development asset linked to Karyopharm Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Karyopharm Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Karyopharm Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
daprodustat
Blood and blood forming organs (B03)US regulatory status: approved. Molecular target: Hypoxia-inducible factor prolyl hydroxylase.
- Target
- Hypoxia-inducible factor prolyl hydroxylase
- Mechanism
- Hypoxia-inducible factor prolyl hydroxylase inhibitor
-
decitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
- Target
- DNA (cytosine-5)-methyltransferase 1
- Mechanism
- DNA (cytosine-5)-methyltransferase 1 inhibitor
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
docetaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
dodecafluoropentane
Various (V08)Various (V08) compound in Karyopharm Therapeutics's portfolio. Mechanism: Ultrasound contrast agent.
- Mechanism
- Ultrasound contrast agent
-
elotuzumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: SLAM family member 7.
- Target
- SLAM family member 7
- Mechanism
- SLAM family member 7 inhibitor
-
Development asset linked to Karyopharm Therapeutics in public FDA and regional records.
-
filgrastim
Antineoplastic and immunomodulating agents (L03)US regulatory status: approved. Molecular target: Granulocyte colony-stimulating factor receptor.
- Target
- Granulocyte colony-stimulating factor receptor
- Mechanism
- Granulocyte colony stimulating factor receptor agonist
-
US regulatory status: approved. Molecular target: Substance-P receptor.
- Target
- Substance-P receptor
- Mechanism
- Neurokinin 1 receptor antagonist
-
Development asset linked to Karyopharm Therapeutics in public FDA and regional records.
-
Development asset linked to Karyopharm Therapeutics in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
- Mechanism
- Mu opioid receptor agonist
-
ibrutinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.
- Target
- Tyrosine-protein kinase BTK
- Mechanism
- Tyrosine-protein kinase BTK inhibitor
-
Development asset linked to Karyopharm Therapeutics in public FDA and regional records.
-
Development asset linked to Karyopharm Therapeutics in public FDA and regional records.
-
Development asset linked to Karyopharm Therapeutics in public FDA and regional records.
-
ixazomib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Karyopharm Therapeutics's portfolio. Molecular target: 26S proteasome.
- Target
- 26S proteasome
- Mechanism
- 26S proteasome inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
netupitant
Alimentary tract and metabolism (A04)US regulatory status: approved. Molecular target: Substance-P receptor.
- Target
- Substance-P receptor
- Mechanism
- Neurokinin 1 receptor antagonist
-
Development asset linked to Karyopharm Therapeutics in public FDA and regional records.
-
Development asset linked to Karyopharm Therapeutics in public FDA and regional records.
-
olanzapine
Nervous system (N05)US regulatory status: approved. Molecular target: D2-like dopamine receptor.
- Target
- D2-like dopamine receptor
- Mechanism
- D2-like dopamine receptor antagonist
-
US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 3A.
- Target
- 5-hydroxytryptamine receptor 3A
- Mechanism
- Serotonin 3a (5-HT3a) receptor antagonist
-
US regulatory status: approved. Molecular target: Activin receptor type-1.
- Target
- Activin receptor type-1
- Mechanism
- Tyrosine-protein kinase receptor FLT3 inhibitor
-
palonosetron
Alimentary tract and metabolism (A04)Alimentary tract and metabolism (A04) compound in Karyopharm Therapeutics's portfolio. Mechanism: Serotonin 3a (5-HT3a) receptor antagonist.
- Mechanism
- Serotonin 3a (5-HT3a) receptor antagonist
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
Development asset linked to Karyopharm Therapeutics in public FDA and regional records.
-
pomalidomide
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: CRL4(CRBN) E3 ubiquitin ligase.
- Target
- CRL4(CRBN) E3 ubiquitin ligase
- Mechanism
- CRL4(CRBN) E3 ubiquitin ligase inhibitor
-
Development asset linked to Karyopharm Therapeutics in public FDA and regional records.
-
rituximab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
ruxolitinib
Dermatologicals (D11)US regulatory status: approved. Mechanism: Tyrosine-protein kinase JAK2 inhibitor.
- Mechanism
- Tyrosine-protein kinase JAK2 inhibitor
-
selinexor
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Exportin-1.
- Target
- Exportin-1
- Mechanism
- Exportin-1 inhibitor
-
Development asset linked to Karyopharm Therapeutics in public FDA and regional records.
-
Development asset linked to Karyopharm Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 1B.
- Target
- 5-hydroxytryptamine receptor 1B
- Mechanism
- Serotonin 1d (5-HT1d) receptor agonist
-
Development asset linked to Karyopharm Therapeutics in public FDA and regional records.
-
Development asset linked to Karyopharm Therapeutics in public FDA and regional records.
-
Development asset linked to Karyopharm Therapeutics in public FDA and regional records.
-
Development asset linked to Karyopharm Therapeutics in public FDA and regional records.
-
Development asset linked to Karyopharm Therapeutics in public FDA and regional records.
-
venetoclax
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Apoptosis regulator Bcl-2.
- Target
- Apoptosis regulator Bcl-2
- Mechanism
- Apoptosis regulator Bcl-2 inhibitor